OncoMark has licenced a proven technology with excellent proof of concept data, which was developed by leading scientists in TCD & UCD. The company will fast-track product development (aiming for CE marking in 2.5 years), aided by a prestigious EU Horizon 2020 SME instrument grant starting in Feb 2016. The development has a clear regulatory & reimbursement pathway, resulting in a premium test with significant margin and return of investment.